Failure to Maintain and Respond to Monthly Pharmacy Reviews
Summary
The facility failed to respond to and maintain monthly medication regimen reviews (MRRs) completed by the consultant pharmacist for multiple residents, including R1, R32, R3, and R24. The facility’s policy required the licensed pharmacist to review each resident’s drug regimen at least monthly, include the medical chart, document any irregularities, communicate those irregularities in writing to the attending physician, medical director, and DON, and make the written communication a permanent part of the medical record. Surveyors found that the facility could not produce complete MRRs or physician responses for several months for these residents. For R1, the record showed diagnoses of dementia and bipolar disorder, severe to moderate cognitive impairment on MDS assessments, and use of multiple psychotropic and other medications including olanzapine, quetiapine, lorazepam, and later Remeron. The chart showed antipsychotic use on a routine basis and no gradual dose reduction attempt. The pharmacy review notes included a recommendation to consider dose reduction for trazodone, but the facility could not provide the MRRs or physician responses for March, July, August, November, or December 2025. Staff also stated they could not locate completed pharmacy reviews, GDRs, or rationales, and the consultant pharmacist stated she emailed the facility multiple times and never received a response. For R32, the record documented diffuse traumatic brain injury, failure to thrive, seizure disorder, major depressive disorder, generalized anxiety disorder, severe cognitive impairment, and use of antipsychotic, antianxiety, antidepressant, and anticonvulsant medications. The pharmacy review notes referenced MRRs in September and December 2025, but the facility could not provide the MRRs or physician responses for those months. For R3, the record documented multiple chronic conditions including stroke, epilepsy, Parkinson’s disease, schizoaffective disorder, anxiety, and diabetes, with psychotropic medication use and prior care plan references to pharmacy review and a contraindicated GDR. The pharmacy review notes referenced MRRs in May 2025, December 2025, and January 2026, but the facility could not produce the MRRs or physician responses. For R24, the record documented anxiety, mild cognitive impairment, and psychotropic medication use; pharmacy review notes referenced MRRs in November and December 2025, but the facility could not provide the MRRs or physician responses. Staff interviews indicated the DON was expected to handle pharmacy reviews, but the facility could not locate the completed reviews, and the consultant pharmacist stated she had never been to the facility for an onsite visit.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.